Alzheimer’s Disease International, Guerchet, M., Prince, M. & Prina, M. Numbers of People with Dementia Worldwide: An Update to the Estimates in the World Alzheimer Report 2015 (Alzheimer’s Disease International, 2020).
Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 16, 391–460 (2020).
Jack, C. R. Jr et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216 (2013).
Article PubMed PubMed Central Google Scholar
Barnes, D. E. & Yaffe, K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 10, 819–828 (2011).
Article PubMed PubMed Central Google Scholar
Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413–446 (2020).
Article PubMed PubMed Central Google Scholar
Long, J. M. & Holtzman, D. M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179, 312–339 (2019).
Article PubMed PubMed Central Google Scholar
Vandenbroucke, J. P. Observational research, randomised trials, and two views of medical science. PLoS Med. 5, e67 (2008).
Article PubMed PubMed Central Google Scholar
Frieden, T. R. Evidence for health decision making-Beyond randomized, controlled trials. N. Engl. J. Med. 377, 465–475 (2017).
Stoiljkovic, M., Horvath, T. L. & Hajós, M. Therapy for Alzheimer’s disease: missing targets and functional markers? Ageing Res. Rev. 68, 101318 (2021).
Article PubMed PubMed Central Google Scholar
Freedman, B. Equipoise and the ethics of clinical research. N. Engl. J. Med. 317, 141–145 (1987).
Fewell, Z., Davey Smith, G. & Sterne, J. A. C. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am. J. Epidemiol. 166, 646–655 (2007).
Hernán, M. A. & Robins, J. M. Estimating causal effects from epidemiological data. J. Epidemiol. Community Health 60, 578–586 (2006).
Article PubMed PubMed Central Google Scholar
Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology. Int. J. Epidemiol. 45, 1866–1886 (2016).
Balshem, H. et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 64, 401–406 (2011).
Lash, T. L. et al. Modern Epidemiology (Wolters Kluwer, 2021).
Koepsell, T. D. Epidemiologic Methods: Studying the Occurrence of Illness (Oxford University Press, 2014).
Dougherty, D. & Conway, P. H. The “3T’s” road map to transform US health care: the “How” of high-quality care. JAMA 299, 2319–2321 (2008).
Trochim, W., Kane, C., Graham, M. J. & Pincus, H. A. Evaluating translational research: a process marker model. Clin. Transl. Sci. 4, 153–162 (2011).
Article PubMed PubMed Central Google Scholar
Sperling, R. A., Jack, C. R. & Aisen, P. S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3, 111cm33 (2011).
Article PubMed PubMed Central Google Scholar
Schneider, J. A., Arvanitakis, Z., Bang, W. & Bennett, D. A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197–2204 (2007).
Nelson, P. T. et al. ‘New Old Pathologies’: AD, PART, and cerebral age-related TDP-43 with sclerosis (CARTS). J. Neuropathol. Exp. Neurol. 75, 482–498 (2016).
Article PubMed PubMed Central Google Scholar
McAleese, K. E. et al. Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. Alzheimers Dement. J. Alzheimers Assoc. 17, 1121–1133 (2021).
Vemuri, P. et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 138, 761–771 (2015).
Article PubMed PubMed Central Google Scholar
White, L. R. et al. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology 86, 1000–1008 (2016).
Article PubMed PubMed Central Google Scholar
Brenowitz, W. D. et al. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement. 13, 654–662 (2017).
Beach, T. G., Monsell, S. E., Phillips, L. E. & Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J. Neuropathol. Exp. Neurol. 71, 266–273 (2012).
Ackley, S. F. et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ 372, n156 (2021).
Article PubMed PubMed Central Google Scholar
Alexander, G. C. et al. Revisiting FDA approval of aducanumab. N. Engl. J. Med. 385, 769–771 (2021).
Anderson, T. S., Ayanian, J. Z., Souza, J. & Landon, B. E. Representativeness of participants eligible to be enrolled in Clinical Trials of Aducanumab for Alzheimer disease compared with Medicare beneficiaries with Alzheimer Disease and Mild Cognitive Impairment. JAMA 326, 1627–1629 (2021).
Article PubMed PubMed Central Google Scholar
Berchtold, N. C. & Cotman, C. W. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol. Aging 19, 173–189 (1998).
Braak, H. & Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351–357 (1997).
Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989–997 (2018).
Article PubMed PubMed Central Google Scholar
Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013).
Article PubMed PubMed Central Google Scholar
Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019).
Article PubMed PubMed Central Google Scholar
Chartier-Harlin, M. C. et al. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844–846 (1991).
Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923 (1993).
Hamilton, R. L. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 10, 378–384 (2000).
Mirra, S. S. et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41, 479–486 (1991).
Newell, K. L., Hyman, B. T., Growdon, J. H. & Hedley-Whyte, E. T. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J. Neuropathol. 58, 1147–1155 (1999).
McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65, 1863–1872 (2005).
Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992).
Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022).
Article PubMed PubMed Central Google Scholar
Pascoal, T. A. et al. In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res. Ther. 10, 74 (2018).
Article PubMed PubMed Central Google Scholar
Clark, C. M. et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA 305, 275–283 (2011).
留言 (0)